<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml"><head><title>R: Relative risks from an unadjusted new-user cohort design</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="stylesheet" type="text/css" href="R.css" />
</head><body>

<table width="100%" summary="page for southworthReplication {EmpiricalCalibration}"><tr><td>southworthReplication {EmpiricalCalibration}</td><td style="text-align: right;">R Documentation</td></tr></table>

<h2>Relative risks from an unadjusted new-user cohort design</h2>

<h3>Description</h3>

<p>Relative risks from an unadjusted new-user cohort design
</p>


<h3>Usage</h3>

<pre>
data(southworthReplication)
</pre>


<h3>Format</h3>

<p>A data frame with 174 rows and 4 variables: </p>
 <dl>
<dt>outcomeName</dt><dd><p>Name of the outcome</p>
</dd>
<dt>trueLogRr</dt><dd><p>The log of the true effect size. Only provided for negative and positive controls, 
is NA for the outcome of interest (GI bleeding).</p>
</dd> <dt>logRr</dt><dd><p>The log of the incidence rate ratio</p>
</dd> <dt>seLogRr</dt><dd>
<p>The standard error of the log of the incidence rate ratio</p>
</dd> </dl>



<h3>Details</h3>

<p>A dataset containing the incidence rate ratios (and standard errors) produced using a new-user 
cohort design that compares new-users of dabigatran to new-users of warfarin for the outcome of 
GI hemorrhage. The dataset includes estimates both for the outcome of interest as well as negative
and positive control outcomes. Subjects are required to have 183 days of continuous observation prior to 
initiating treatment, a prior diagnosis of atrial fibrillation, and are required to have no prior 
exposure to either dabigatran or warfarin. The study computes an incidence rate ratio without 
any adjustment for confounders. Time at risk is defined as the time on the drug. The original 
study (Southworth 2013) uses the 'Mini-Sentinel Database'. For our replication, we use the Optum 
databases since both databases are US insurance claims databases. We analyzed 5,982 
dabigatran-exposed and 19,155 warfarin-exposed subjects. For more information on this set see 
Schuemie et al (2017).
</p>


<h3>References</h3>

<p>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration 
for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci 
U S A. 2018 Mar 13;115(11):2571-2577
</p>
<p>Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl 
J Med 368(14):1272-1274, 2013
</p>

<hr /><div style="text-align: center;">[Package <em>EmpiricalCalibration</em> version 2.1.0 <a href="00Index.html">Index</a>]</div>
</body></html>
